OVERVIEW

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes is organized by i3 Health and will be held from May 16, 2023 - May 15, 2024.

Statement of Need:
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al., 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, and impacts on quality of life (NCCN, 2023). Remaining up to date on emerging treatment options and management strategies for HNSCC is vital. This activity led by Assuntina Sacco, MD, Associate Professor of Medicine at Moores Cancer Center of UC San Diego Health, will provide new insights and real-world guidance for improved outcomes in recurrent and metastatic HNSCC.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  •  Distinguish histopathological, molecular, and clinical biomarkers that can inform prognosis and management of HNSCC
  • Incorporate emerging efficacy and safety data on novel immune checkpoint inhibitors into personalized care plans for patients with advanced recurrent/metastatic HNSCC
  • Apply strategies to prevent and mitigate immune-mediated adverse events
  • Evaluate supportive care measures that can help optimize survivorship care in patients who have received treatment for advanced recurrent/metastatic HNSCC

In this activity, discover new insights and real-world evidence for improved patient outcomes in recurrent/metastatic head and neck squamous cell carcinoma from Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine at the University of California, San Diego Health. Learn about differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, impacts on quality of life, and more. 

Credits

Physicians:
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development:
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for .9 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.  

  • 1 AMA PRA Category 1 Credit™
  • 1 MOC
  • 1 Contact Hour
  • 1 Hours
  • TARGET AUDIENCE

    PhysicianNursingPhysician AssistantOncologyFamily PhysiciansHealthcare ProfessionalsSurgical OncologistsNurse PractitionersOtolaryngology-head and neck surgeryRadiation OncologistsMedical OncologistsPrimary Care Providers

    SPECIALITIES

    Head and Neck PathologyHead and Neck SurgeryOtolaryngology Head and Neck SurgeryRadiation Oncology

    RELATED ONLINE COURSES